Fasoracetam crystalline forms
AssigneeThe Children's Hospital of Philadelphia
InventorsTom Leyssens, Bram Harmsen
Life of this patent
Estimating the term…
Abstract
The disclosure is directed to crystalline forms and mixtures thereof of R-fasoracetam. Such crystalline forms include Form II monohydrate R-fasoracetam and the anhydrate form of R-fasoracetam. The disclosure further includes mixtures of the anhydrate form of R-fasoracetam together with one or more of Form I monohydrate R-fasoracetam and Form II monohydrate R-fasoracetam.
Claims13
A mixture of fasoracetam monohydrate Form I, fasoracetam monohydrate Form II, and anhydrate fasoracetam, wherein:
- the fasoracetam monohydrate Form I has an x-ray powder diffraction pattern comprising one or more peaks chosen from peaks at 7.2±0.2°2θ and 12.9±0.2°2θ;
- the fasoracetam monohydrate Form II has an x-ray powder diffraction pattern comprising one or more peaks chosen from peaks at 5.7±0.2°2θ and 11.3±0.2°2θ;
- and
- the anhydrate fasoracetam has an x-ray powder diffraction pattern comprising one or more peaks chosen from peaks at 8.9±0.2°2θ, 12.3±0.2°2θ, and 13.1±0.2°2θ.
A mixture of anhydrate fasoracetam and fasoracetam monohydrate Form I or fasoracetam monohydrate Form II, wherein:
- the fasoracetam monohydrate Form I has an x-ray powder diffraction pattern comprising one or more peaks chosen from peaks at 7.2±0.2°2θ and 12.9±0.2°2θ;
- the fasoracetam monohydrate Form II has an x-ray powder diffraction pattern comprising one or more peaks chosen from peaks at 5.7±0.2°2θ and 11.3±0.2°2θ;
- and
- the anhydrate fasoracetam has an x-ray powder diffraction pattern comprising one or more peaks chosen from peaks at 8.9±0.2°2θ, 12.3±0.2°2θ, and 13.1±0.2°2θ.
A mixture of fasoracetam monohydrate Form I, fasoracetam monohydrate Form II, and anhydrate fasoracetam, wherein the mixture has an x-ray powder diffraction pattern comprising one or more peaks chosen from peaks at 5.7±0.2°2θ, 7.2±0.2°2θ, and 12.9±0.2°2θ.
A mixture of fasoracetam monohydrate Form I, fasoracetam monohydrate Form II, and anhydrate fasoracetam, wherein the mixture has an x-ray powder diffraction pattern comprising one or more peaks chosen from peaks at 5.7±0.2°2θ or 11.3±0.2°2θ or both, and 7.2±0.2°2θ, and one or more of the peaks chosen from peaks at 8.9±0.2°2θ, 12.3±0.2°2θ, and 13.1±0.2°2θ.
Dependencies are inferred from the claim text.